Niraparib,orally active small molecule PARP inhibitor developed by Tesaro to Rx ovarian cancer, granted fast track designtn by USFDA in 2016
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
@GSK
#dishmanpharma
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
@GSK
#dishmanpharma
Dishman Carbogen makes the API for the drug, has been supplying APIs to GSK from 2017
The approval will help Niraparib grow multifold,big positive for Dishman’s CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
The approval will help Niraparib grow multifold,big positive for Dishman’s CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumors have completely or partially responded to platinum-based chemotherapy treatments
Zejula sales $295 million 2019
#dcal
Zejula sales $295 million 2019
#dcal
Forward on WhatsApp
Glaxo expects 1 Billion USD of Revenues from Niraparib(Zejula)
Dishman is the API supplier for it.API component is 5% ...So around 50 Million USD
With 60% Margins
#DCAL #dishmancarbogenamcis @GSK
Glaxo expects 1 Billion USD of Revenues from Niraparib(Zejula)
Dishman is the API supplier for it.API component is 5% ...So around 50 Million USD
With 60% Margins
#DCAL #dishmancarbogenamcis @GSK
• • •
Missing some Tweet in this thread? You can try to
force a refresh
